Shanghai Miracure Pharmaceuticals Co., Ltd. (688373)
SSE SSE Primary Summary
688373 Chart
People also search for
Shanghai Miracure Pharmaceuticals Co., Ltd. (688373) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Shanghai Miracure Pharmaceuticals Co., Ltd. ever had a stock split?
Shanghai Miracure Pharmaceuticals Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Dr. Yuan Zhengyu Ph.D. CEO | SSE Exchange | CNE100005PX4 ISIN |
| CN Country | 205 Employees | - Last Dividend | 3 Apr 2019 Last Split | - IPO Date |
Overview
Shanghai MicuRx Pharmaceutical Co., Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs designed to meet unmet medical needs. Founded in 2007 and based in Shanghai, China, the company has dedicated its resources to target a range of bacterial infections and diseases that currently lack effective treatments. With a robust pipeline of antibiotics and other therapeutic agents, Shanghai MicuRx is at the forefront of addressing the global challenge of multidrug-resistant bacterial infections, alongside other critical health conditions such as kidney disease, COVID-19, and tumors.
Products and Services
- Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4)
Developed as next-generation oxazolidinone antibiotics, these products are designed to combat multidrug-resistant gram-positive bacteria, offering a new solution for treating infections caused by these hard-to-treat pathogens.
- MRX-8
An innovative polymyxin antibiotic in development, MRX-8 targets multidrug-resistant Gram-negative bacteria, providing a potential new option for treating severe infections caused by these bacteria.
- MRX-5
Focused on addressing the challenge of multidrug-resistant gram-negative bacteria, MRX-5 is part of Shanghai MicuRx's ongoing efforts to expand its portfolio of treatments for infections caused by these resistant organisms.
- MRX-7
This product is being developed to specifically target multidrug-resistant gram-positive bacteria, enhancing the company's arsenal against antibiotic-resistant infections.
- MRX-15 and MRX-17
Targeting kidney disease, these products represent Shanghai MicuRx's expansion into treatments for chronic conditions, demonstrating the company's commitment to addressing a broader spectrum of unmet medical needs beyond infectious diseases.
- MRX-18
Aimed at the treatment of COVID-19, MRX-18 reflects Shanghai MicuRx's rapid response to global health emergencies and its ability to pivot resources towards pressing public health threats.
- MRX-23
Developed for the treatment of tumors, MRX-23 signifies Shanghai MicuRx's venture into oncology, leveraging its research and development capabilities to confront cancer.
